Literature DB >> 17037994

Survival after colorectal cancer in patients with Crohn's disease: A nationwide population-based Danish follow-up study.

Mette Larsen1, Hanne Mose, Mette Gislum, Mette V Skriver, Peter Jepsen, Bente Nørgård, Henrik T Sørensen.   

Abstract

BACKGROUND AND AIMS: Patients with Crohn's disease (CD) are at increased risk of colorectal cancer (CRC), but little is known about the impact of CD on CRC prognosis. Based on nationwide population-based registries, we compared survival among CRC patients with CD and CRC patients without CD.
METHODS: We used the Danish Cancer Registry and the Danish Hospital Discharge Registry to identify all patients diagnosed with CRC, with and without CD, in Denmark between 1977 and 1999. We ascertained the stage distribution at the time of CRC diagnosis and 1- and 5-yr survival both for patients with Crohn-associated CRC and patients with non-Crohn CRC. Cox regression was used to compute hazard ratios (HRs), adjusting for gender, age, calendar year, and stage.
RESULTS: We identified 100 CRC patients with CD and 71,438 CRC patients without CD. At the time of diagnosis, patients with CD were younger, but stage distributions were similar in the two groups. The overall HR for CRC with CD compared to CRC without CD was 1.82 (95% CI 1.36-2.43) after 1 yr of follow-up, and 1.57 (95% CI 1.24-1.99) after 5 yr of follow-up. Subanalyses showed that the effect of CD on CRC survival was more pronounced in the youngest patients (0-59 yr), in men, and in patients whose tumors had regional spread.
CONCLUSIONS: We found that CD worsens the prognosis of CRC, particularly CRC with regional spread.

Entities:  

Mesh:

Year:  2006        PMID: 17037994     DOI: 10.1111/j.1572-0241.2006.00857.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

Review 1.  A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer.

Authors:  Ian S Reynolds; Aobhlinn O'Toole; Joseph Deasy; Deborah A McNamara; John P Burke
Journal:  Int J Colorectal Dis       Date:  2017-01-11       Impact factor: 2.571

2.  Survival of Colorectal Cancer in Patients With or Without Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Baochi Ou; Jingkun Zhao; Shaopei Guan; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

3.  Is ulcerative colitis associated with survival among older persons with colorectal cancer in the US? A population-based case-control study.

Authors:  Aasma Shaukat; Nadim I Salfiti; Daniel J Virnig; David H Howard; Shanthi V Sitaraman; Jonathan M Liff; Frank A Lederle
Journal:  Dig Dis Sci       Date:  2011-11-19       Impact factor: 3.199

4.  Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.

Authors:  Mahesh Devarasetty; Aleksander Skardal; Kyle Cowdrick; Frank Marini; Shay Soker
Journal:  Tissue Eng Part A       Date:  2017-10       Impact factor: 3.845

5.  Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry.

Authors:  Scott V Adams; Dennis J Ahnen; John A Baron; Peter T Campbell; Steven Gallinger; William M Grady; Loic LeMarchand; Noralane M Lindor; John D Potter; Polly A Newcomb
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

6.  Crohn's disease-associated colorectal cancer in Japan: report of four cases.

Authors:  Tadataka Hayashi; Toshio Nakamura; Kiyotaka Kurachi; Atsuko Fukazawa; Akihito Nakajima; Koichi Nakamura; Shohachi Suzuki; Hiroyuki Konno
Journal:  Int J Colorectal Dis       Date:  2007-08-24       Impact factor: 2.571

Review 7.  Colorectal cancer in inflammatory bowel disease: review of the evidence.

Authors:  D S Keller; A Windsor; R Cohen; M Chand
Journal:  Tech Coloproctol       Date:  2019-01-30       Impact factor: 3.781

8.  Colorectal cancer risk in Crohn's disease.

Authors:  Hugh-James Freeman
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

9.  Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth.

Authors:  Anita L Ray; Kiersten L Berggren; Sebastian Restrepo Cruz; Gregory N Gan; Ellen J Beswick
Journal:  Int J Cancer       Date:  2017-12-12       Impact factor: 7.396

10.  Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003.

Authors:  Rune Erichsen; Peter Jepsen; Hendrik Vilstrup; Anders Ekbom; Henrik Toft Sørensen
Journal:  Eur J Epidemiol       Date:  2009-06-26       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.